NCT01033292

A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Resistant Recurrent Ovarian Cancer

Study identifier: NCT01033292
Full study details on clinicaltrials.gov

Name of PARP Inhibitor used in study:

Iniparib (Sanofi Aventis)

Eligibility:

• Histological diagnosis of epithelial ovarian carcinoma, fallopian tube cancer, or primary peritoneal carcinoma
• Completion of only one previous course of chemotherapy which contained a platinum therapy, with resistance to that regimen.
• Measurable disease, defined by at least one lesion that can be accurately measured in at least one dimension.

Type of study:

Phase II study

Treatment:

BSI-201 in combination with gemcitabine and carboplatin.

Study site:

Massachusetts
Massachusetts Ceneral Hospital
Boston, Massachusetts, 02114
Contact: Michael Birrer, MD, PhD 617-724-8540 mbirrer@partners.org
Contact: Maria Roche, NP 617-724-8540 mroche@partners.org
Principal Investigator: Michael Birrer, MD, PhD

Web design by Rareheron Web Design